29/09/2023 – AB Science today reports its revenues for the first half of 2023 and provides an update on its activities Download PDF Post navigationPreviousPrevious post:Update on the EMA timetable for examination of the masitinib marketing authorization application in ALSNextNext post:The clinical development of masitinib in sickle cell disease is among the 19 winning projects under the sixth call for “Hospital-Inuversity Research in health (RHU)”Related PostsAB Science webcast – Masitinib in Sickle Cell Disease30 November 2023AB Science will host a live webcast on Thursday November 30, 2023, to present the masitinib development program in sickle cell disease28 November 2023The clinical development of masitinib in sickle cell disease is among the 19 winning projects under the sixth call for “Hospital-Inuversity Research in health (RHU)”27 November 2023Update on the EMA timetable for examination of the masitinib marketing authorization application in ALS18 September 2023AB Science receives Notice of Allowance for European patent covering masitinib in the treatment of metastatic castrate refractory prostate cancer (mCRPC)26 June 2023AB Science announces issuance of a Canadian patent for masitinib in the treatment of ALS with protection until 20371 June 2023
AB Science will host a live webcast on Thursday November 30, 2023, to present the masitinib development program in sickle cell disease28 November 2023
The clinical development of masitinib in sickle cell disease is among the 19 winning projects under the sixth call for “Hospital-Inuversity Research in health (RHU)”27 November 2023
Update on the EMA timetable for examination of the masitinib marketing authorization application in ALS18 September 2023
AB Science receives Notice of Allowance for European patent covering masitinib in the treatment of metastatic castrate refractory prostate cancer (mCRPC)26 June 2023
AB Science announces issuance of a Canadian patent for masitinib in the treatment of ALS with protection until 20371 June 2023
